{
    "nctId": "NCT04438577",
    "briefTitle": "Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery",
    "officialTitle": "Evaluation of the Feasibility and Efficacy of Lidocaine Mucilage-ICG as an Optical Agent to Detect Cancer Tissue Delineation During Breast-conserving Surgery",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Margin width",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female at least 18 years old\n* Histologically or cytologically confirmed breast carcinoma\n* Patients planned to receive a breast-conserving surgery\n* Patients received a preoperative breast magnetic resonance imaging\n* Informed consent form understood and signed\n* Patient agrees to all follow-up visits\n* Eastern Cooperative Oncology Group(ECOG) performance status 0 to 1 within 14 days of study entry\n* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the surgery\n\nExclusion Criteria:\n\n* Psychiatric or other condition that may interfere with the study\n* Known allergy or contraindication to any study drug\n* Patients received neoadjuvant therapies\n* Patients received an excision biopsy of the tumor\n* Breast feeding period\n* Pregnant (female of childbearing potential only)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}